drugset / Trial / NCT05374954
Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above
Phase 3
Unknown
4200 enrolled
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd. · collabHunan Provincial Center for Disease Control and Prevention · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This is a randomized, double blind, positive controlled study to evaluate the safety and immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above who have been vaccinated with 2 or 3 doses of COVID-19 Vaccine (Vero Cell), Inactivated manufactured by Beijing Institute of Biological Products, Co., Ltd.
Timeline
- Start
- 2022-05-10
- Primary completion
- 2022-09-25
- Completion
- 2023-11-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CoronaVac | Vaccine | — | Intramuscular |
| Subject | Omicron COVID-19 Vaccine (Vero Cell), Inactivated | Vaccine | — | Intramuscular |